Terms: = Lung cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Treatment
254 results:
1. The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
Cheng B; Li C; Li J; Gong L; Liang P; Chen Y; Zhan S; Xiong S; Zhong R; Liang H; Feng Y; Wang R; Wang H; Zheng H; Liu J; Zhou C; Shao W; Qiu Y; Sun J; Xie Z; Liang Z; Yang C; Cai X; Su C; Wang W; He J; Liang W
Signal Transduct Target Ther; 2024 Apr; 9(1):93. PubMed ID: 38637495
[TBL] [Abstract] [Full Text] [Related]
2. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
Zhong H; Sun S; Chen J; Wang Z; Zhao Y; Zhang G; Chen G; Zhou M; Zhou J; Du Y; Wu L; Xu Z; Mei X; Zhang W; He J; Cui J; Zhang Z; Luo H; Liu W; Sun M; Wu J; Shen Y; Zhang S; Yang N; Wang M; Lu J; Li K; Yao W; Sun Q; Yue H; Wang L; Ye S; Li B; Zhuang X; Pan Y; Zhang M; Shu Y; He Z; Pan L; Ling Y; Liu S; Zhang Q; Jiao S; Han B
Lancet Respir Med; 2024 May; 12(5):355-365. PubMed ID: 38309287
[TBL] [Abstract] [Full Text] [Related]
3. [Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].
Chen YQ; Zhang YD; Yan H; Qin HY; Huang Z; Zhang X; Xiang SQ; Hu XQ; Wu F; Zhang YC; Zeng L; Yang N
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):282-289. PubMed ID: 38246773
[No Abstract] [Full Text] [Related]
4. Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non-small cell lung cancer and mutated EGFR.
Vila Pérez A; Alegre-Del Rey EJ; Fénix-Caballero S; Špacírová Z; Rosado Varela P; Olry de Labry Lima A
Support Care Cancer; 2023 Dec; 32(1):67. PubMed ID: 38150163
[TBL] [Abstract] [Full Text] [Related]
5. Single-cell and spatial transcriptomics reveal POSTN
Chen C; Guo Q; Liu Y; Hou Q; Liao M; Guo Y; Zang Y; Wang F; Liu H; Luan X; Liang Y; Guan Z; Li Y; Liu H; Dong X; Zhang X; Liu J; Xu Q
Clin Transl Med; 2023 Dec; 13(12):e1515. PubMed ID: 38115703
[TBL] [Abstract] [Full Text] [Related]
6. Multiplex Immunohistochemistry Staining for Paraffin-embedded lung cancer Tissue.
Yang Y; Huang H; Li L; Yang Y
J Vis Exp; 2023 Nov; (201):. PubMed ID: 38078595
[TBL] [Abstract] [Full Text] [Related]
7. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
[TBL] [Abstract] [Full Text] [Related]
8. Identification of a Novel Oxidative Stress- and Anoikis-Related Prognostic Signature and Its Immune Landscape Analysis in Non-Small Cell lung cancer.
Zhao H; Huang Y; Tong G; Wu W; Ren Y
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003378
[TBL] [Abstract] [Full Text] [Related]
9. Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study.
Mander ES; Merrick CB; Nicholson HA; Lord HK; Ferguson MJ; Smith G
BMJ Open; 2023 Nov; 13(11):e076715. PubMed ID: 37989364
[TBL] [Abstract] [Full Text] [Related]
10. Impact of Waiting Times on Mortality in Advanced Stage Non-Small Cell lung cancer: A 10-Year Retrospective Cohort Study in Thailand.
Vichapat V; Chantasartrassamee P; Reungwetwattana T
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3419-3428. PubMed ID: 37898846
[TBL] [Abstract] [Full Text] [Related]
11. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Chang HC; Wang CC; Tseng CC; Huang KT; Chen YM; Chang YP; Lai CH; Fang WF; Lin MC; Chuang HY
Thorac Cancer; 2023 Nov; 14(32):3208-3216. PubMed ID: 37737541
[TBL] [Abstract] [Full Text] [Related]
12. Comparative Effectiveness of Lurbinectedin for the treatment of Relapsed Small Cell lung cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
Boyne DJ; Dawe DE; Shakir H; Joe-Uzuegbu O; Farah E; Pabani A; Baratta C; Brenner DR; Cheung WY
Target Oncol; 2023 Sep; 18(5):697-705. PubMed ID: 37656263
[TBL] [Abstract] [Full Text] [Related]
13. MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.
Nakanishi T; Yoneshima Y; Okamura K; Yanagihara T; Hashisako M; Iwasaki T; Haratake N; Mizusaki S; Ota K; Iwama E; Takenaka T; Tanaka K; Yoshizumi T; Oda Y; Okamoto I
Cancer Sci; 2023 Oct; 114(10):4101-4113. PubMed ID: 37565582
[TBL] [Abstract] [Full Text] [Related]
14. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
[TBL] [Abstract] [Full Text] [Related]
15. Patterns of care for people with small cell lung cancer in Victoria, 2011-19: a retrospective, population-based registry data study.
Huang J; Faisal W; Brand M; Smith S; Alexander M; Briggs L; Conron M; Duffy M; John T; Langton D; Lesage J; MacManus M; Mitchell P; Olesen I; Parente P; Philip J; Samuel E; Torres J; Underhill CR; Zalcberg JR; Harden S; Stirling R
Med J Aust; 2023 Aug; 219(3):120-126. PubMed ID: 37365486
[TBL] [Abstract] [Full Text] [Related]
16. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With cancer: A Randomized Clinical Trial.
Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
[TBL] [Abstract] [Full Text] [Related]
17. Identification of FKBP10 prognostic value in lung adenocarcinoma patients with surgical resection of brain metastases: A retrospective single-institution cohort study.
Liu ZD; Wang SQ; Li S; He J; Wang SH; Cai HQ; Wan JH
Clinics (Sao Paulo); 2023; 78():100212. PubMed ID: 37201304
[TBL] [Abstract] [Full Text] [Related]
18. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced cancers Treated With Immunotherapy.
Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
[TBL] [Abstract] [Full Text] [Related]
19. Unradical Surgery for Locally-Advanced Thymoma: Is it time to evolve Perspectives?
Mastromarino MG; Bacchin D; Aprile V; Ceccarelli I; Korasidis S; Lenzini A; Ambrogi MC; Lucchi M
Lung Cancer; 2023 Jun; 180():107214. PubMed ID: 37104878
[TBL] [Abstract] [Full Text] [Related]
20. [CT perfusion combined with energy spectrum imaging to evaluate the short-term efficacy of bronchial arterial chemoembolization for lung cancer].
Lai LQ; Lin GH; Chen WY; Tu JF; Ji JS
Zhonghua Nei Ke Za Zhi; 2023 May; 62(5):539-544. PubMed ID: 37096281
[No Abstract] [Full Text] [Related]
[Next]
